Not medical advice. Talk to your provider before using any peptide. Full disclaimer
LL-37
Beginner tier: 50 mcg, daily · community consensus
Also known as: hCAP-18 (precursor), CAMP, FALL-39
Three human wound healing trials. That is LL-37's clinical resume, and it is more than most antimicrobial peptides can claim. LL-37 is the only cathelicidin produced by the human body, a 37-amino-acid peptide your neutrophils release as a first-line defense against bacteria, viruses, and fungi. The Phase IIb HEAL trial (148 patients) confirmed wound healing activity at the 0.5 mg/mL dose, with a 6x higher healing rate constant versus placebo. Community users inject it subcutaneously for biofilm infections and immune support, though every clinical trial to date used topical application. That route gap matters.
What Is LL-37?
LL-37 (also called hCAP-18 in its precursor form, molecular weight 4493.3 Da) is a 37-amino-acid cationic antimicrobial peptide produced by neutrophils, epithelial cells, and barrier tissues. The Phase IIb HEAL trial (PMC9298190, 2022, n=148) produced the strongest clinical signal: healing rate constant 6 times higher than placebo in venous leg ulcers (P=0.003). Its amphipathic alpha-helical structure lets it punch through bacterial membranes on contact, and it penetrates the extracellular polymeric matrix of biofilms, the protective slime that makes embedded bacteria up to 1,000 times more antibiotic-resistant.
Community use centers on subcutaneous injection at 50 to 200 mcg daily for chronic infections, wound healing, and immune support. The practical challenge is pharmacological. Its serum half-life is estimated at under 30 minutes (no human measurement), and plasma proteins actively inhibit both antimicrobial and anticancer activity. The working theory is that SC injection creates a local depot effect rather than meaningful systemic distribution.
Two additional human trials round out the clinical picture. A Phase I/II study [1] showed positive results for venous leg ulcers. A separate RCT for diabetic foot ulcers (Springer 2023) confirmed safety with a positive healing trend. All three trials used topical application. No human SC pharmacokinetic data exists.
How LL-37 Works
Proteinase 3 cleaves LL-37 from its precursor protein hCAP-18 inside neutrophil granules. The released peptide carries a net positive charge that drives electrostatic attraction to negatively charged bacterial membranes. Once bound, LL-37's hydrophobic face inserts into the lipid bilayer. It forms toroidal pores or carpets the membrane surface until structural integrity collapses. Bacterial lysis follows within minutes.
Biofilm disruption works through a different path. LL-37 penetrates the extracellular polymeric matrix surrounding embedded bacteria. It disrupts quorum sensing, the chemical signaling bacteria use to coordinate group defense. Conventional antibiotics often cannot breach this matrix at all; LL-37 reaches bacteria that have been hiding from treatment for months.
Beyond direct killing, LL-37 binds lipopolysaccharide and lipoteichoic acid. This neutralizes bacterial endotoxins before they trigger excessive inflammatory signaling. It also activates formyl peptide receptor-like 1 (FPRL1), pulling neutrophils, monocytes, and T-cells toward infection sites. Wound healing gets a separate boost through VEGF upregulation (angiogenesis), keratinocyte migration, and collagen deposition.
Dose determines the inflammatory direction. Low concentrations suppress pro-inflammatory cytokine release from macrophages. Higher concentrations amplify inflammation. That concentration-dependent switch makes dose selection more important with LL-37 than with most peptides in the immune category.
LL-37 Benefits
- LL-37 benefits center on antimicrobial defense and wound healing, with the strongest evidence in biofilm disruption.
- Biofilm penetration is LL-37's defining advantage. It reaches bacteria embedded in protective matrices that make them up to 1,000x more resistant to standard antibiotics.
- The HEAL trial (n=148) confirmed wound healing activity. The 0.5 mg/mL arm showed a 6x higher healing rate constant versus placebo (P=0.003, PMC9298190).
- Broad-spectrum antimicrobial coverage spans bacteria, viruses, and fungi through direct membrane disruption, not receptor-mediated killing that bacteria can evolve around.
- LPS neutralization reduces endotoxin-driven inflammation. LL-37 binds bacterial lipopolysaccharide before it triggers the inflammatory cascade.
- Community users consistently report reduced recurrence of chronic infections when stacking LL-37 with Thymosin Alpha-1 for combined innate and adaptive immune coverage.
LL-37: Science vs Community Consensus
Wound healing is the only human-trial-supported use (topical application).
Read the evidence (key study, limitations)
Phase I/II RCT [1] showed positive results for hard-to-heal venous leg ulcers. Phase IIb HEAL trial (PMC9298190, n=148) missed primary endpoint but 0.5 mg/mL arm had 6× higher healing rate constant vs placebo (P=0.003). Diabetic foot ulcer RCT (Springer 2023) found safe with positive healing trend. No SC injection human PK or efficacy data exists.
Phase IIb HEAL trial: Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers (PMC9298190, 2022, n=148)
All human trials used topical application, not SC injection. No human SC PK/PD data. Activity inhibited in human plasma by serum proteins. Mixed oncology profile (pro-tumor in 7 cancer types vs anti-tumor in colon/gastric/hematologic). No regulatory approval for any route.
Used primarily for chronic/recurrent infections, biofilm disruption, immune support, and wound healing via SC injection.
Read the reports (what users report 4, common issues 5)
Daily dosing is the universal community standard: 2×/week site frequencies are not used. Regarded as a niche but potent tool; less popular than BPC-157/TB-500 for wound healing.
- Biofilm disruption for chronic hard-to-clear infections: cited as LL-37's primary niche vs antibiotics
- Wound healing acceleration: most research-backed use, 3 human topical trials
- Reduced susceptibility to recurrent infections (immune support)
- Complement to BPC-157 in combined wound/infection healing protocols
- Injection site pain and redness common, especially above 100 mcg
- Flu-like immune activation response on initiation: transient but unpleasant
- Short half-life creates genuine uncertainty about whether SC dosing achieves meaningful tissue concentrations beyond local site
- Very potent: narrow therapeutic window; overdose risk at higher doses (pro-inflammatory at ≥10 mcg/mL)
- Niche: limited community data compared to BPC-157, TB-500
Science supports wound healing via topical application; community uses SC injection for wound healing + infections + immune support. Mechanisms (local AMP activity, biofilm disruption) are consistent across both, but routes differ and SC bioavailability data is absent. Community daily dosing is pharmacologically more defensible than site's 2×/week given the estimated <30 min systemic half-life.
LL-37 Dosage Guide
Reconstitution math for a 5 mg vial with 2 mL bacteriostatic water: total volume is 200 units on an insulin syringe. Each unit delivers 25 mcg. So 50 mcg is 2 units, 100 mcg is 4 units, 125 mcg is 5 units, 200 mcg is 8 units.
Start at 50 mcg daily (2 units) for the first week regardless of experience level. LL-37 is potent enough that skipping the titration week creates unnecessary risk.
The dosing frequency listed in most structured references is 2 to 3 times per week. Community consensus and pharmacological logic both point to daily dosing. With an estimated systemic half-life under 30 minutes (no human measurement), twice-weekly injections leave zero circulating peptide between doses.
Source matters more with LL-37 than many peptides. HPLC purity certificates showing 98% or higher and mass spectrometry confirmation of the correct molecular weight (4493.3 Da) are the baseline. Endotoxin (LAL) test certificates are non-negotiable for any antimicrobial peptide. Solid-phase peptide synthesis avoids the LPS contamination risk that E. coli expression systems carry.
Reconstituted vials go in the refrigerator at 2 to 8 degrees Celsius. Use within 4 weeks. Discard if you see particles, cloudiness, or color change.
LL-37 is an endogenous human peptide but is produced locally at mucosal surfaces, not circulating systemically. Repeated SC injection exposes the immune system to LL-37 in a context where it may trigger ADA (anti-drug antibody) formation, potentially reducing efficacy or causing hypersensitivity. The documented pro-tumor and pro-inflammatory risks at higher concentrations make continuous unmonitored use unwise. Community consensus of 4–6 week cycles reflects precautionary cycling pending better long-term data.
- Reduced therapeutic response after initial efficacy (suggests ADA or receptor adaptation)
- Unexpected local reactions after previously well-tolerated doses
- Any autoimmune flare or psoriasis worsening
- Persistent systemic symptoms beyond first week of a new cycle
Or use the universal Peptide Calculator for any peptide.
LL-37 Protocols by Goal
Expected: Reduced frequency/severity of recurrent infections; enhanced innate immune response at local tissue level
Monitor: Monitor injection site reactions. If flu-like symptoms beyond day 5, reduce dose.
How to Use LL-37
- 1Step 1
Gather supplies: LL-37 vial (5 mg lyophilized), bacteriostatic water, alcohol swabs, 29 to 31 gauge insulin syringe (0.5 mL or 1 mL).
- 2Step 2
Reconstitute by adding 2 mL of bacteriostatic water to the 5 mg vial. Direct the stream against the glass wall, not directly onto the powder. Swirl gently until fully dissolved. Do not shake. This gives you 25 mcg per unit on an insulin syringe.
- 3Draw your dose
For a 50 mcg beginner dose, pull to the 2 unit mark. For 100 mcg (moderate), pull to 4 units. For 125 mcg (intermediate wound healing protocol), pull to 5 units. For 200 mcg (advanced), pull to 8 units.
- 4Clean the injection site with an alcohol swab
Pinch a fold of skin on the abdomen (avoiding 2 inches around the navel) or outer thigh. Insert the needle at a 45 degree angle into the subcutaneous layer.
- 5Inject slowly and hold for 5 seconds before withdrawing
Rotate injection sites with each dose.
- 6Timing is morning for all protocols
Dose daily, not 2 to 3 times per week. The sub-30-minute systemic half-life makes daily dosing the pharmacologically sound choice.
- 7Step 7
Store the reconstituted vial in the refrigerator at 2 to 8 degrees Celsius. Discard after 4 weeks or if the solution changes appearance.
Alternative Routes
0.5–1.6 mg/mL concentration applied directly to wound 2×/week vs 50–200 mcg SC daily
Topical is the ONLY route with human trial data. Requires pharmaceutical-grade formulation (0.5–1.6 mg/mL in cream/gel vehicle). Research-grade lyophilized powder dissolved in water or saline is not equivalent to trial formulations. No self-compounded topical protocols validated in community.
LL-37 Stacking Protocols
Works With
Complementary immune coverage: LL-37 targets innate immunity (direct antimicrobial, AMP activity); TA-1 targets adaptive immunity (T-cell differentiation, TLR signaling). Frequently combined for broad immune support.
LL-37 50–125 mcg SC daily + TA-1 1.5 mg SC 2×/week
Most commonly cited wound healing stack. BPC-157 promotes angiogenesis and tissue repair via systemic distribution; LL-37 provides local antimicrobial + wound healing at site. Combined effect on wound closure and infection control.
LL-37 100–125 mcg SC daily + BPC-157 250–500 mcg SC daily near wound site
Anti-inflammatory complement to LL-37. Useful when LL-37-driven immune activation is too strong or wound has significant inflammatory component. KPV counterbalances LL-37's pro-inflammatory risk at higher doses.
LL-37 100 mcg SC daily + KPV 500 mcg–1 mg SC daily. Use with caution; monitor for immunosuppression.
Avoid
Blunt LL-37 immune-stimulating effects. Corticosteroids suppress the innate immune pathways LL-37 activates, negating therapeutic benefit.
Do not combineLL-37 binds heparin-binding sites; potential interaction with heparin and related anticoagulants. Monitor coagulation parameters.
Reduces LL-37 immune-modulating effects. Concurrent use undermines both agents' therapeutic intent.
Estimated Cost
Pricing updated 2026-04-09
LL-37 Side Effects
LL-37 becomes pro-inflammatory at tissue concentrations at or above 10 mcg/mL. That makes it one of the few peptides where overdosing doesn't just waste product; it actively reverses the therapeutic goal. High-grade fever, pronounced systemic inflammation, and immune flare are all possible above this threshold. Pro-tumor activity has been documented across seven cancer types (lung, ovarian, breast, prostate, melanoma, liver, skin SCC). Anyone with active malignancy or raised cancer risk should treat this as a hard contraindication.
Published side effects from the three human trials (all topical application) were mild: local irritation at the wound site with no systemic adverse events. SC injection side effects come from community reports, not controlled trials.
Injection site pain and redness are the most commonly reported issues, particularly at doses above 100 mcg. Community sources describe localized nodules that can persist for 2 to 3 days when injection technique is poor or sites aren't rotated.
Flu-like symptoms during the first 3 to 5 days reflect immune activation from macrophage stimulation and cytokine release. Most reports indicate these resolve by day 5 to 7. Persistent flu-like symptoms beyond day 5 or any high-grade fever warrant immediate dose reduction or cessation.
LL-37 is raised in psoriatic skin lesions and induces Type I interferon relevant to systemic lupus erythematosus. Anyone with active psoriasis, lupus, or other autoimmune conditions should not use this peptide. Worsening of autoimmune flares has been reported; stop immediately if any flare occurs.
The systemic half-life is estimated at under 30 minutes (no human measurement), and plasma proteins inhibit LL-37 activity. This creates genuine uncertainty about whether SC injection achieves tissue concentrations sufficient for antimicrobial effect beyond the local injection site.
Contraindications: pregnancy or breastfeeding (no safety data), known hypersensitivity to cathelicidin-derived peptides, active autoimmune conditions (psoriasis, lupus), active malignancy, and children under 18.
When to seek medical attention: high-grade fever, signs of excessive immune activation, any autoimmune flare, or persistent injection site nodules lasting beyond 3 days.
Common Issues & Solutions
Injection site redness/pain: Expected at doses ≥100 mcg. Reduce to 50 mcg and titrate more slowly. Ensure proper SC injection technique and rotate sites. Persistent hard nodule >3 days warrants dose reduction.
Flu-like symptoms on initiation: Reflects immune activation (cytokine release from macrophage stimulation). Transient and expected within days 1–5. Persistent symptoms beyond day 5 or high-grade fever = reduce dose or stop.
No apparent effect: Given an estimated <30 min systemic half-life and plasma protein inhibition of LL-37 activity, systemic effects are mechanistically uncertain. Clinical trials only support local/topical wound healing. Manage expectations for systemic immune effects.
Pro-inflammatory flare (high fever, significant systemic inflammation): LL-37 becomes pro-inflammatory at concentrations ≥10 mcg/mL in tissues. Reduce dose immediately. Do not re-escalate above last well-tolerated dose.
Psoriasis or autoimmune worsening: LL-37 is elevated in psoriatic lesions and induces Type I interferon in SLE. Stop immediately if any autoimmune flare. LL-37 is contraindicated in active autoimmune disease.
Ask AI about this page
Ask AI for a second opinion on LL-37 dosing and side effects
Contraindications
- Pregnancy or breastfeeding: no safety data available in these populations
- Known hypersensitivity to LL-37 or cathelicidin-derived peptides
- Active autoimmune conditions (psoriasis, lupus): LL-37 is elevated in psoriatic lesions and may worsen flares
- Active malignancy: LL-37 has mixed effects on tumor cells and may promote angiogenesis
- Children under 18: not studied in pediatric populations
Drug Interactions
- Immunosuppressants (corticosteroids, cyclosporine, methotrexate): may blunt LL-37 immune-stimulating effects
- Other antimicrobial peptides or immune-stimulating peptides (Thymosin Alpha-1, KPV): additive immune activation; use caution with stacking
- Anticoagulants (warfarin, heparin): LL-37 may interact with heparin-binding sites; monitor coagulation parameters
- Topical antimicrobials: potential additive effects when LL-37 is used alongside wound care agents
Product Quality
LL-37 is a 37-amino-acid AMP with an amphipathic alpha-helical structure critical for bioactivity. Proper folding and purity are essential: truncated or misfolded product may be biologically inactive or cytotoxic. Endotoxin contamination is a significant risk in AMP synthesis (LPS is a frequent contaminant in bacterial expression systems). Plasma protein inhibition means even correctly synthesized product may have limited systemic activity. No FDA-approved SC formulation exists as a quality benchmark.
- HPLC purity certificates ≥98% plus mass spectrometry confirmation of correct molecular weight (4493.3 Da for LL-37) are the baseline checks
- Request endotoxin (LAL) test certificates: endotoxin-free is essential for any AMP
- Solid-phase peptide synthesis (SPPS) avoids the LPS contamination risk of E. coli expression
- Reconstitute in sterile bacteriostatic water only; use within 4 weeks refrigerated
- Discard if visible particles, cloudiness, or color change observed after reconstitution
Recommended Monitoring
| Test | When | Target |
|---|---|---|
| Comprehensive metabolic panel (CMP) | Baseline before start; repeat at 4 weeks if using >100 mcg/day | Not listed |
| CBC with differential | Baseline; optional at 4 weeks for immune monitoring | Not listed |
| C-reactive protein (CRP) / ESR | Baseline; repeat at 2 weeks if flu-like symptoms present | Not listed |
| Wound measurement (if wound healing indication) | Weekly during treatment cycle: photograph and measure wound dimensions | ≥25% wound area reduction by week 4 is a reasonable efficacy threshold based on clinical trial outcomes |
Rule out any hepatic or renal effects from immune activation; baseline safety check
Track immune cell counts, particularly neutrophils and lymphocytes, as markers of LL-37's immunomodulatory effect
Confirm immune activation is resolving, not escalating. Persistently elevated CRP with symptoms warrants dose reduction or cessation.
Only objective way to assess efficacy. Clinical trials (PMID 25041740) used wound area reduction as primary endpoint.
LL-37 Before and After
Treatment initiation. LL-37 begins circulating and interacting with target tissues. Injection site redness or mild soreness is common at this stage. No noticeable systemic changes yet.
Early immune activation. Innate immune cell recruitment increases at infection or wound sites. Some users report reduced redness or drainage from chronic wounds. Mild flu-like symptoms may occur as immune activity ramps up.
Antimicrobial and wound-healing effects become more apparent. Biofilm disruption allows better immune clearance of chronic infections. Wound granulation tissue formation and re-epithelialization may accelerate.
Peak therapeutic window. Measurable improvements in wound closure, reduced bacterial load at infection sites, and stronger innate immune markers. Cycle typically ends here: reassess before continuing.
What to Expect
Days 1 to 3 (Initiation): Local antimicrobial peptide activity begins at the injection site. Neutrophils and monocytes start migrating toward the area through FPRL1 activation. Expect injection site redness and mild soreness. Some users report mild fatigue as the immune system ramps up. No systemic changes at this stage.
Days 4 to 10 (Early immune activation): Innate immune cell recruitment picks up at infection or wound sites. LPS neutralization and cytokine modulation are underway. Flu-like symptoms typically peak during this window, then fade. Some users notice reduced drainage from chronic wounds or improved skin at wound edges. Most flu-like symptoms (fatigue, mild fever, body aches) clear by day 7.
Weeks 2 to 3 (Antimicrobial and wound healing effect): Biofilm disruption, if applicable, starts improving immune clearance of entrenched infections. Keratinocyte migration and angiogenesis through VEGF upregulation accelerate wound closure. Visible improvements in wound tissue quality or reduced infection signs are commonly reported. Earlier immune activation symptoms have typically resolved.
Weeks 4 to 6 (Peak therapeutic window): Clinical trials achieved maximum wound healing response by weeks 12 to 13 with topical application. SC injection timelines run shorter given the local-only mechanism hypothesis. Most users report measurable changes in wound healing or infection status by this point. Cycles typically end here; reassess before extending.
Detailed Timeline: Science vs Community
Local AMP activity at injection site. Neutrophil and monocyte chemotaxis via FPRL1 activation.
Injection site redness, mild soreness. No systemic changes. Some report mild fatigue as immune system activates.
Innate immune cell recruitment increases at infection/wound sites. LPS neutralization and cytokine modulation.
Flu-like symptoms peak then subside. Some report reduced drainage from chronic wounds or improved skin around wound edges.
Biofilm disruption (if applicable) improves immune clearance. Keratinocyte migration and angiogenesis via VEGF upregulation accelerate wound closure.
Visible improvement in wound tissue quality or reduced infection signs reported. Immune activation symptoms resolve.
Maximum wound healing response in clinical trials achieved by weeks 12–13 (topical studies). SC injection timeline shorter given local-only mechanism hypothesis.
Most users report noticeable changes in wound healing or infection status by week 4–6. Cycle typically ends here; reassess before extending.
Pharmacokinetics
Source: Serum t1/2 <30 minutes is an estimate, not a value from the cited study. That study found no apparent breakdown in chronic wound fluid for up to 24 hours ex vivo (PMID 21547341)
Pharmacokinetics: Active Dose Over Time
t½ = <30 minutes (estimated, serum); no breakdown in chronic wound fluid over 24 h (ex vivo)Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.
Molecular Profile
Is LL-37 Legal?
LL-37 has no FDA approval for any indication or route of administration. It carries a preclinical regulatory status. The three completed human trials (Phase I/II for venous leg ulcers, Phase IIb HEAL trial, diabetic foot ulcer RCT) all used topical formulations under investigational protocols.
LL-37 is sold online labeled "for research purposes only" or "not for human consumption." No compounding pharmacy protocols exist for systemic LL-37, and no FDA-approved SC formulation provides a quality benchmark.
Athletes should verify WADA status before use. Antimicrobial peptides are not specifically listed on the WADA prohibited list, but peptide hormones and growth factors are a monitored category. Consult a sports medicine physician if competition testing applies.
This content is for educational and informational purposes only. It does not constitute medical advice. Consult a licensed healthcare provider before using any peptide.
Evidence grade: Phase 2 trial (Peptide Evidence Gap, October 2026)
Who Should Consider LL-37
- Individuals with chronic or recurrent bacterial infections
- Patients with biofilm-associated infections (chronic wounds, implant infections)
- Those with slow-healing or non-healing wounds
- People with compromised innate immune function
- Individuals recovering from skin injuries or surgical wounds
Related Peptides
What Changed for LL-37
- RegulatoryEffective
Nominators withdrew 12 peptides (GHK-Cu for injectable routes only) from 503A category 2, announced Apr 15, 2026, per the FDA 503A categories list.
What this does not mean: Leaving category 2 does not put a peptide on the 503A bulks list or make it eligible for compounding. That takes FDA rulemaking, and none has been proposed (Federal Register search, Oct 6, 2026).
Also covers: BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, Epithalon, GHK-Cu, Dihexa, PEG-MGF, Melanotan II
Source: FDA, Bulk drug substances nominated for use in compounding under section 503A (categories list, updated April 22, 2026; the April 15, 2026 notice version is archived beside it) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)
Dates to watch
- Committee review
FDA intends to consult its compounding advisory committee on adding these peptides to the 503A bulks list, per FDA.
What this does not mean: No meeting date is set yet. A committee vote is advice to FDA, not a rule; the 503A bulks list changes only through notice-and-comment rulemaking.
Also covers: GHK-Cu, Dihexa, Melanotan II, PEG-MGF
Peptide Schedule Research TeamReviewed Apr 7, 20269 Citations
References
- [1]Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial (Gronberg et al., Wound Repair Regen 2014) (opens in a new tab)PubMed (opens in a new tab)PubMed
Additional References
- LL-37, the only human member of the cathelicidin family of antimicrobial peptides (Biochim Biophys Acta 2006) (opens in a new tab)PubMed 16716248PubMed
- Cathelicidin LL-37: a multitask antimicrobial peptide (Arch Immunol Ther Exp 2010) (opens in a new tab)PubMed 20049649PubMed
- Wound healing activity of the human antimicrobial peptide LL37 (J Invest Dermatol 2011) (opens in a new tab)PubMed 21693141PubMed
- The human cathelicidin antimicrobial peptide LL-37 as a potential treatment for polymicrobial infected wounds (Front Immunol 2013) (opens in a new tab)PubMed 23840194PubMed
- Stability of the cathelicidin peptide LL-37 in a non-healing wound environment (Acta Derm Venereol 2011) (opens in a new tab)PubMed 21547341PubMed
- Therapeutic potential of cathelicidin peptide LL-37 in a murine sepsis model (Int J Mol Sci 2020) (opens in a new tab)PubMed 32825174PubMed
- PMC9298190 (PMC9298190) (opens in a new tab)PubMed
- Springer 2023 (DOI: 10.1007/s00403-023-02657-8) (opens in a new tab)PubMed
Related Tools
Storage & Stability
Frequently Asked Questions
How popular is LL-37?
Niche. A popularity tier (hot, popular, emerging or niche), based on search volume and community activity.
Reddit: Low. Community mentions on Reddit: Low–moderate; appears in r/Peptides injury/infection threads. Open r/Peptides (opens in a new tab).
1,000 papers on PubMed, the US library of medical research. Search them on PubMed (opens in a new tab).
Moderate search interest. A band for how often people search Google for the name each month.
These come from this site's peptide records. They are not live counts.